GSK’s Blenrep combination approved in Singapore for treatment of relapsed/refractory Multiple myeloma

Akeso’s AK157D1 cleared for phase 1 trial in Solid tumors

CStone Pharmaceuticals receives NMPA IND approval for CS5007

Enhertu significantly improved PFS as 1L treatment in HER2-mutant advanced NSCLC in the phase 3...

Iza-bren phase 3 trial met its primary endpoint in locally advanced/metastatic NSCLC

Akiram Therapeutics and ITM signed a Lu-177 supply agreement to support AKIR001 development in Solid...